Endo International plc provided financial guidance for the second quarter of 2020. The company expects total revenues to decline in the low 20% range in the second quarter compared to the first quarter of 2020. This decline primarily reflects an expected decline in Branded Pharmaceuticals revenue in the low to mid-60% range compared to the first quarter driven by a reduction in physician-administered products included in the Specialty Products portfolio, resulting from office closures and a decline in patients electing to be treated.